Mariposa Therapeutics is developing MP5219 as a potential first-in-class, disease-modifying therapy for Epidermolysis Bullosa Simplex (EBS), a chronic genetic condition that causes skin to blister and tear. The company plans to use the seed funding to carry out pre-clinical development, secure scientific advice, and engage early with regulators ahead of clinical progression. It intends to establish a Cardiff research facility with laboratory space in 2026 and to recruit scientific staff in Wales to support formulation development and future manufacturing. Leadership includes CEO Dr David Howat (appointed October 2024) and chief scientific officer Dr Lucy Sykes. Financially, Mariposa completed a £750,000 seed round led by the Development Bank of Wales with co-investment from DEBRA Research gGmbH and the founders, positioning the company to pursue further funding for clinical development.

Total raised

$1M

Funding rounds

1

Latest round

Seed

Latest activity

Mar 2026